A phase I trial of PRN1008, a novel reversible covalent inhibitor of Brutonʼs tyrosine kinase, in healthy volunteers

DOI: 10.1111/bcp.13351
British Journal of Clinical Pharmacology, 2017, 83, 2367-2376.

#	Paper	IF	Citations
70	A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers. *British Journal of Clinical Pharmacology*, **2017**, 83, 2367-2376	3.8	55
69	Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?. *Expert Review of Hematology*, **2018**, 11, 185-194	2.8	38
68	The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review. *European Journal of Medicinal Chemistry*, **2018**, 151, 315-326	6.8	84
67	Perspective From the 5th International Pemphigus and Pemphigoid Foundation Scientific Conference. *Frontiers in Medicine*, **2018**, 5, 306	4.9	15
66	Versatile Bioconjugation Chemistries of ortho-Boronyl Aryl Ketones and Aldehydes. *Accounts of Chemical Research*, **2018**, 51, 2198-2206	24.3	36
65	Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances. *Journal of Medicinal Chemistry*, **2018**, 61, 9030-9058	8.3	31
64	From bench to bedside: evolving therapeutic targets in autoimmune blistering disease. *Journal of the European Academy of Dermatology and Venereology*, **2019**, 33, 2239-2252	4.6	4
63	The pathogenesis of bullous skin diseases. *Journal of Translational Autoimmunity*, **2019**, 2, 100014	4.1	9
62	What is novel in the clinical management of pemphigus. *Expert Review of Clinical Pharmacology*, **2019**, 12, 973-980	3.8	7
61	Treatment of pemphigus vulgaris: part 2 - emerging therapies. *Expert Review of Clinical Immunology* , **2019**, 15, 1061-1071	5.1	6
60	Current Clinical Trials in Pemphigus and Pemphigoid. *Frontiers in Immunology*, **2019**, 10, 978	8.4	37
59	Optimization of novel reversible Bruton's tyrosine kinase inhibitors identified using Tethering-fragment-based screens. *Bioorganic and Medicinal Chemistry*, **2019**, 27, 2905-2913	3.4	7
58	Spotlight Commentary: How to prove pharmacology of immunomodulatory drugs in a phase 1 trial?. *British Journal of Clinical Pharmacology*, **2019**, 85, 1389-1390	3.8	1
57	Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018). *Expert Opinion on Therapeutic Patents*, **2019**, 29, 217-241	6.8	29
56	Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK). *Journal of Medicinal Chemistry*, **2019**, 62, 3228-3250	8.3	47
55	Pharmacological advances in pemphigus. *Current Opinion in Pharmacology*, **2019**, 46, 44-49	5.1	8
54	Covalent Inhibition in Drug Discovery. *ChemMedChem*, **2019**, 14, 889-906	3.7	101

53	Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis: phase I to II clinical trials. *Expert Opinion on Investigational Drugs*, **2019**, 28, 1113-1123	5.9	4
52	In Vivo Targeting of Endogenous Proteins with Reactive Small Molecules. **2020**, 281-307		
51	Efficacy of a Bruton's Tyrosine Kinase Inhibitor (PRN-473) in the treatment of canine pemphigus foliaceus. *Veterinary Dermatology*, **2020**, 31, 291-e71	1.8	9
50	Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases. *Journal of Medicinal Chemistry*, **2020**, 63, 12526-12541	8.3	12
49	Driving Potency with Rotationally Stable Atropisomers: Discovery of Pyridopyrimidinedione-Carbazole Inhibitors of BTK. *ACS Medicinal Chemistry Letters*, **2020**, 11, 2195-2203	4.3	4
48	Selective inhibition of thromboinflammation in COVID-19 by Btk inhibitors. *Platelets*, **2020**, 31, 989-992	3.6	4
47	Open trial of Bruton's tyrosine kinase inhibitor (PRN1008) in the treatment of canine pemphigus foliaceus. *Veterinary Dermatology*, **2020**, 31, 410-e110	1.8	7
46	Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell lymphomas. *Cancers*, **2020**, 12,	6.6	27
45	Covalent Kinase Inhibitors: An Overview. *Topics in Medicinal Chemistry*, **2020**, 43-94	0.4	3
44	Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers. *British Journal of Clinical Pharmacology*, **2021**, 87, 1824-1838	3.8	2
43	Covalent drugs in development for immune-mediated diseases. *Annual Reports in Medicinal Chemistry*, **2021**,	1.6	
42	Antineoplastic kinase inhibitors: A new class of potent anti-amoebic compounds. *PLoS Neglected Tropical Diseases*, **2021**, 15, e0008425	4.8	2
41	Considering patient age when treating multiple sclerosis across the adult lifespan. *Expert Review of Neurotherapeutics*, **2021**, 21, 353-364	4.3	0
40	Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease. *Journal of Immunology*, **2021**, 206, 1454-1468	5.3	20
39	Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease. *Cancers*, **2021**, 13,	6.6	16
38	Emerging Therapies in Immune Thrombocytopenia. *Journal of Clinical Medicine*, **2021**, 10,	5.1	7
37	B-cell targeted therapies in pemphigus. *Italian Journal of Dermatology and Venereology*, **2021**, 156,	1.2	0
36	Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 655489	5.7	3

35	Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study. *British Journal of Dermatology*, **2021**, 185, 745-755	4	13
34	Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	9
33	Therapeutic approaches and targets for treatment of autoimmune bullous diseases. *Dermatologic Therapy*, **2021**, 34, e15032	2.2	
32	Immune thrombocytopenia: options and new perspectives. *Blood Coagulation and Fibrinolysis*, **2021**, 32, 427-433	1	1
31	Management of Adult Patients with Immune Thrombocytopenia (ITP): A Review on Current Guidance and Experience from Clinical Practice. *Journal of Blood Medicine*, **2021**, 12, 653-664	2.3	5
30	Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases. *Molecules*, **2021**, 26,	4.8	10
29	Experts' review: the emerging roles of romiplostim in immune thrombocytopenia (ITP). *Expert Opinion on Biological Therapy*, **2021**, 21, 1383-1393	5.4	
28	Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus. *Frontiers in Medicine*, **2021**, 8, 708071	4.9	1
27	Effects of the Btk-Inhibitors Remibrutinib (LOU064) and Rilzabrutinib (PRN1008) With Varying Btk Selectivity Over Tec on Platelet Aggregation and Bleeding Time. *Frontiers in Cardiovascular Medicine*, **2021**, 8, 749022	5.4	1
26	Recent progress in covalent warheads for in vivo targeting of endogenous proteins. *Bioorganic and Medicinal Chemistry*, **2021**, 47, 116386	3.4	4
25	Promises and pitfalls of targeted agents in chronic lymphocytic leukemia.. **2020**, 3, 415-444		2
24	Bruton's Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease. *Drugs* , **2021**, 81, 1605-1626	12.1	5
23	Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168). *Clinical and Translational Science*, **2021**,	4.9	3
22	Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors.. *Journal of Medicinal Chemistry*, **2021**,	8.3	10
21	Research Progress of BTK Inhibitors in the Treatment of Inflammatory and Autoimmune Diseases. *Hans Journal of Medicinal Chemistry*, **2022**, 10, 70-83	0	
20	Bruton's tyrosine kinase inhibition-an emerging therapeutic strategy in immune-mediated dermatological conditions.. *Allergy: European Journal of Allergy and Clinical Immunology*, **2022**,	9.3	3
19	Discovery of Reversible Covalent Bruton's Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib).. *Journal of Medicinal Chemistry*, **2022**,	8.3	2
18	A thorough QTc study to evaluate the effects of oral rilzabrutinib administered alone and with ritonavir in healthy subjects.. *Clinical and Translational Science*, **2022**,	4.9	

17	The Development of BTK Inhibitors: A Five-Year Update. *Molecules*, **2021**, 26,	4.8	7
16	Translational autoimmunity in pemphigus and the role of novel Bruton tyrosine kinase inhibitors.. *Journal of Translational Autoimmunity*, **2022**, 5, 100156	4.1	
15	Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia.. *New England Journal of Medicine*, **2022**, 386, 1421-1431	59.2	2
14	Table_1.DOCX. **2019**,		
13	Investigational drugs for immune thrombocytopenia.. *Expert Opinion on Investigational Drugs*, **2022**, 1-13	5.9	1
12	Development of New Drugs for Autoimmune Hemolytic Anemia. *Pharmaceutics*, **2022**, 14, 1035	6.4	2
11	Bruton Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives. *Journal of Clinical Medicine*, **2022**, 11, 2807	5.1	2
10	Novel Therapies to Address Unmet Needs in ITP. *Pharmaceuticals*, **2022**, 15, 779	5.2	1
9	Immunotherapy for Pemphigus: Present and Future. *Frontiers in Medicine*, 9,	4.9	0
8	Next-generation Bruton tyrosine kinase (BTK) inhibitors potentially targeting BTK C481S mutation- Recent developments and Perspectives.. **2022**, 22,		2
7	Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently?. 13,		1
6	BTK Inhibitors in Haematology: Beyond B Cell Malignancies. **2022**,		0
5	Refractory/relapse thrombocytopenia in a patient with Evans' syndrome successfully treated with zanubrutinib.		1
4	Existing and Investigational Medications for Refractory Chronic Spontaneous Urticaria: Safety, Adverse Effects, and Monitoring. **2022**,		0
3	Comparison of Intermolecular Interactions of Irreversible and Reversible Inhibitors with Bruton Tyrosine Kinase via Molecular Dynamics Simulations. **2022**, 27, 7451		1
2	B-cell targeted therapy of pemphigus.		0
1	Discovery of BGB-8035, a Highly Selective Covalent Inhibitor of Bruton Tyrosine Kinase for B-Cell Malignancies and Autoimmune Diseases. **2023**, 66, 4025-4044		0